Please assess the completion status of the following clinical trial:

Trial Title: Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of idiopathic Parkinson's disease, Hoehn and Yahr stage 2.0 to 4.0.~2. Presence of drug-induced dyskinesias~3. Age\>40 years.~4. Willingness and ability to comply with the study requirements and give informed consent.~Exclusion Criteria:~1. Atypical parkinsonian syndrome due to drugs, metabolic disorders, encephalitis, or degenerative diseases.~2. History of stereotaxic brain surgery.~3. Clinical history of dementia.~4. Known major psychiatric disorder, major depression, schizophrenia. Known alcoholism or substance dependence within previous 12 months.~5. History of major hematological, renal, or hepatic abnormalities.~6. Known coronary artery disease including angina or myocardial infarction within the last 6 months. Significant cardiovascular disease including cardiac failure, unstable angina or life-threatening arrhythmia within the last 6 months.~7. History of stroke within the last 6 months.~8. Abnormal EKG consistent with cardiac ischemia.~9. Treatment with nitrates. Nitrates or any NO donors in any dosage form (oral, sublingual, transdermal, inhalation, or aerosols).~10. Malignant hypertension or SBP . 180 or \<90, or DBP .110 or \<50.~11. History of priapism.~12. Known history of retinitis pigmentosa.~13. Positive pregnancy test.~14. History of bleeding disorder.~15. Patients with active peptic ulcer disease associated with bleeding.~16. Unwillingness to use adequate contraceptive methods if of childbearing potential.~17. Patients with medical or psychological condition or social circumstances that would impair their ability to participate in the study.~18. Use of Viagra or any experimental drugs within 30 days of screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Viagra (Type: EXPERIMENTAL): subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
- Placebo comparator (Type: PLACEBO_COMPARATOR): subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).